AbbVie Revenue Rises on Strength in Immunology, Neuroscience - WSJ
Source: WSJ ·
AbbVie Revenue Rises on Strength in Immunology, Neuroscience WSJAbbVie lifts annual profit forecast as immunology drugs continue to fuel growth ReutersAs Skyrizi and Rinvoq dominate AbbVie's Q3, analysts ask what's next Fierce PharmaHere's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings Yahoo FinanceIs AbbVie a Buy After Its Latest Earnings Report? The Motley Fool
From the source
- EnglishUnited States - Deutsch - English - Español - Français - Italiano - All languages - Afrikaans - azərbaycan - bosanski - català - Čeština - Cymraeg - Dansk - Deutsch - eesti - EnglishUnited Kingdom - EspañolEspaña - EspañolLatinoamérica - euskara - Filipino - FrançaisCanada - FrançaisFrance - Gaeilge - galego - Hrvatski - Indonesia - isiZulu - íslenska - Italiano - Kiswahili - latviešu - lietuvių - magyar - Melayu - Nederlands - norsk - o‘zbek - polski - PortuguêsBrasil - PortuguêsPortugal - română - shqip - Slovenčina - slovenščina - srpski (latinica) - Suomi - Svenska - Tiếng Việt - Türkçe - Ελληνικά - беларуская - български - кыргызча - қазақ тілі - македонски - монгол - Русский - српски - Українська - ქართული - հայերեն - עברית - اردو - العربية - فارسی - አማርኛ - नेपाली - मराठी - हिन्दी - অসমীয়া - বাংলা - ਪੰਜਾਬੀ - ગુજરાતી - ଓଡ଼ିଆ - தமிழ் - తెలుగు - ಕನ್ನಡ - മലയാളം - සිංහල - ไทย - ລາວ - မြန်မာ - ខ្មែរ - 한국어 - 日本語 - 简体中文 - 繁體中文 - 繁體中文香港 - EnglishUnited States - Deutsch -…
BestAIBroker analysis
- Finance-aware sentiment: positive (+0.60 on a -1 to +1 scale).
- Event classification: OTHER.
- Market importance score: 37/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
- Symbols referenced: ABBV.